StateWatch: Fall 2018
The FDA has approved a non-opioid, percutaneous electrical nerve field stimulator device as an aid to reduce opioid withdrawal symptoms during detoxification.
Off Patent Medications & Drug Patent Expiration: Quarterly Drug Update
Managing pharmaceutical decisions in a claim can greatly impact the outcome of that claim, from recovery time to costs. Therefore, close monitoring of pharmacy changes and compliance updates is vital. In our previous quarterly update, we took a closer look at the utilization of generic drugs and 'me-too' medications.
The Power of Perspective: Seeing the Full Picture of a Claim
Every decision matters when handling an auto casualty or workers’ compensation claim. A poor decision could cause a delay in helping an injured worker get back to work, while a well-informed choice could help an auto insurance claimant receive compensation for their injuries sooner rather than later.
Workers’ Compensation Medical Price Index: Q2 2018
The National CPI for All Services reported by the Bureau of Labor Statistics as of August 2018 is 125.31 when adjusted to Q1 2006, which reflects a 0.9 percent increase since Q4 2017.
Premiums Written: Q3 2018 Casualty Must-Reads
This quarter, Mitchell was featured in Claims Journal, where Vice President of Medical Management Services Jackie Payne shared insights into how precertification and utilization review play a role in workers’ compensation and present an effective method in the defense against rising medical costs.
StateWatch: Bill Review August / September 2018
Keep current with new legislation and its potential effect on your organization.
Implications of Epidiolex FDA Approval on Workers' Compensation
In June 2018, the Federal Drug Administration (FDA) approved Epidiolex, the first plant-derived cannabinoid medicine in the United States. With several states already moving toward legalization of medical marijuana, this is a major step for the federal government.
Stay Ahead in P&C
Get monthly insights from Enlyte experts to tackle your toughest claims challenges.